Africa Centres for Disease Control and Prevention and Aspen Pharmacare are strengthening efforts to expand vaccine production capacity across Africa as the continent seeks greater pharmaceutical independence and improved health security. The partnership forms part of broader continental plans to reduce reliance on imported vaccines following supply shortages experienced during the COVID-19 pandemic, as reported by Reuters.
The collaboration focuses on scaling local manufacturing, improving technology transfer, and building sustainable vaccine supply chains capable of serving African markets. Aspen Pharmacare, Africa’s largest pharmaceutical manufacturer, has already invested heavily in sterile manufacturing and vaccine production infrastructure at its facilities in South Africa.
Africa CDC has been leading the African Union’s ambition to ensure that at least 60% of vaccines used in Africa are manufactured locally by 2040. Officials say partnerships with companies such as Aspen are critical to developing the industrial capabilities, skilled workforce, and financing needed to achieve long-term vaccine self-sufficiency across the continent.
Analysts note that the initiative could help strengthen Africa’s healthcare resilience while creating new opportunities in biotechnology, pharmaceutical manufacturing, and medical research. However, they also caution that sustained government procurement support, regulatory coordination, and long-term financing will be essential to ensuring the viability of local vaccine production ecosystems.
